Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

Documenti analoghi

• Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
  di: Taneja, Amit, et al.
  Pubblicazione: (2019)
• Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
  di: Maher, Toby M, et al.
  Pubblicazione: (2019)
• Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
  di: Namour, Florence, et al.
  Pubblicazione: (2016)
• Population pharmacokinetics and pharmacodynamics of oral etoposide
  di: Toffoli, Giuseppe, et al.
  Pubblicazione: (2001)
• Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects
  di: Dingemanse, Jasper, et al.
  Pubblicazione: (2006)